Tevogen Bio Holdings Inc. (TVGN) Stock Score, Valuation & Financial Research

Tevogen Bio Holdings Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TVGN

Tevogen Bio Holdings Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.49. These figures are a research snapshot, not a buy or sell recommendation.

What Tevogen Bio Holdings Inc. does

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company that focuses on developing off-the-shelf, precision T cell therapies. The company utilizes its Tevogen.AI initiative to integrate artificial intelligence into drug development, laboratory processes, and clinical trials to optimize efficiency and patient outcomes.

Products and services

  • The company is developing CD8+ cytotoxic T lymphocyte (CD8+ CTL) therapies for the treatment of infectious diseases, cancers, and other disorders.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • CD 8 Technology Services LLC — Provides services under a Master Services and Facilities Agreement. Source

Business relationships and partnerships

  • Microsoft for Startups — Enrollment in the program to explore the deployment of artificial intelligence-powered target detection to accelerate product development. Source

Business strengths to evaluate

  • Proprietary CD8+ cytotoxic T lymphocyte technology platform Source
  • Integration of artificial intelligence via Tevogen.AI Source

Business risks and research considerations

  • Clinical-stage development risks and regulatory uncertainty Source
  • Cybersecurity vulnerabilities in internal and contractor systems Source

Sources: Company research source · CD 8 Technology Services LLC

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TVGN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 6.49
Market capitalization:
27.03M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -21.61M
Free cash flow:
USD -12.39M
Cash:
USD 1.08M
Total debt:
USD 3.04M
EPS:
USD -5.83

What stands out

  • Free cash flow is USD -12.39M, negative for the stored period.
  • The balance sheet shows USD 1.08M of cash versus USD 3.04M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 1.96M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TVGN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TVGN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is TVGN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for TVGN to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of TVGN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research TVGN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.